Jan 8 (Reuters) - Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy. (Reporting by Christy Santhosh; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +2.85% | +2.20% | +17.33% |
May. 14 | Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.33% | 117M | |
+37.78% | 723B | |
+32.82% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.64% | 244B | |
-4.13% | 208B | |
+10.63% | 210B | |
+9.32% | 169B |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar's blood cancer therapy succeeds in trial